Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell- Lung Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00084853" target="_blank" >RIV/00216224:14110/15:00084853 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell- Lung Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study
Popis výsledku v původním jazyce
Background: Adjuvant cisplatinum-based chemotherapy is recommended in patients with stages IB (> 4 cm), IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Vinorelbine with cisplatin are preferable drugs in this indication, but the side effects of this treatment were not negligible in big adjuvant trials. Carboplatin with vinorelbine given intravenously switched to orally were applied in a multicentre prospective study SWITCH I to give better comfort, higher tolerabilityand comparable effectivenes as standard adjuvant chemotherapy. The recruitment period started in January 12th, 2005 and lasted till September 5th, 2008. Conclusion: Adjuvant chemotherapy with carboplatinum and vinorelbine given intravenously on the day1 and orally on the day 8 in 21 day regimen appears to be a comfortable and tolerable therapy in radically resected NSCLC.
Název v anglickém jazyce
Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell- Lung Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study
Popis výsledku anglicky
Background: Adjuvant cisplatinum-based chemotherapy is recommended in patients with stages IB (> 4 cm), IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Vinorelbine with cisplatin are preferable drugs in this indication, but the side effects of this treatment were not negligible in big adjuvant trials. Carboplatin with vinorelbine given intravenously switched to orally were applied in a multicentre prospective study SWITCH I to give better comfort, higher tolerabilityand comparable effectivenes as standard adjuvant chemotherapy. The recruitment period started in January 12th, 2005 and lasted till September 5th, 2008. Conclusion: Adjuvant chemotherapy with carboplatinum and vinorelbine given intravenously on the day1 and orally on the day 8 in 21 day regimen appears to be a comfortable and tolerable therapy in radically resected NSCLC.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
FC - Pneumologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů